title: Apoptosis induction by acyclic retinoid: a molecular basis of 'clonal deletion' therapy for hepatocellular carcinoma.
abstract: We have shown previously that administration of acyclic retinoid to cirrhotic patients who had undergone curative treatment of preceding hepatocellular carcinoma (HCC) induced the disappearance of serum lectin-reactive alpha-fetoprotein (AFP-L3) and subsequently reduced the incidence of second liver cancers. AFP-L3 is a tumor marker that indicates the presence of occult tumors below the detection limit by diagnostic images. Therefore, we have proposed a new concept of 'clonal deletion' therapy with acyclic retinoid for the cancer chemoprevention against HCC. Such eradication of AFP-L3-producing latent malignant (or premalignant) cells from the liver suggested a new strategy to prevent HCC, which may be involved in the same category as cancer chemotherapy. In the present series of studies, we explored the molecular mechanism of 'clonal deletion' and found a novel mechanism of apoptosis induction by the retinoid. We have demonstrated a modification of a retinoid receptor, RXRalpha, by mitogen-activated protein (MAP) kinase-dependent phosphorylation, resulting in the loss of transactivating activity. This may lead HCC cells to be resistant to natural retinoic acid. However, acyclic retinoid restored the function of phosphorylated RXRalpha and induced its downstream pro-apoptotic genes including tissue transglutaminase, an enzyme that is implicated in apoptosis. Tissue transglutaminase-dependent apoptosis in HCC cells was independent of the activation of caspases. This novel mechanism of retinoid-induced apoptosis may give a clue to understand the molecular mechanism of clonal deletion.
authors.affiliation: First Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Okuno
authors.forename: T
authors.initials: T
authors.lastname: Sano
authors.forename: R
authors.initials: R
authors.lastname: Matsushima-Nishiwaki
authors.forename: S
authors.initials: S
authors.lastname: Adachi
authors.forename: K
authors.initials: K
authors.lastname: Akita
authors.forename: Y
authors.initials: Y
authors.lastname: Okano
authors.forename: S
authors.initials: S
authors.lastname: Kojima
authors.forename: H
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000517:prevention & control*; D018890:Chemoprevention; D017637:Clonal Deletion; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000517:prevention & control*; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014212:Tretinoin; C034534:3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid